DOP2000000081A - Metodos para usar 22045, una fosfodisterasa humana de nuclosidos ciclicos - Google Patents
Metodos para usar 22045, una fosfodisterasa humana de nuclosidos ciclicosInfo
- Publication number
- DOP2000000081A DOP2000000081A DO2000000081A DO2000000081A DOP2000000081A DO P2000000081 A DOP2000000081 A DO P2000000081A DO 2000000081 A DO2000000081 A DO 2000000081A DO 2000000081 A DO2000000081 A DO 2000000081A DO P2000000081 A DOP2000000081 A DO P2000000081A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- phosphodiesterase
- methods
- polynucleotides
- polypeptides
- relates
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 7
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 7
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000000556 agonist Substances 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- 238000004458 analytical method Methods 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Metodos para usar una fosfodiesterasa humana de nuclebtidos ciclicos que pertenece a la superfamilia de las fosfodiesterasas de mamiferos. La invención se relaciona tambien con metodos para usar los polinucleótidos que codifican la fosfodiesterasa. La invencion se relaciona con metodos para usar los polipeptidos y los polinucleotidos de la fosfodiesterasa como un blanco para la diagnosis y el tratamiento de afecciones mediadas o relacionadas con la fosfodiesterasa. La invencion se relaciona ademas con metodos para el analisis de drogas que usan los polipeptidos y los polinucleótidos de la fosfodiesterasa para identificar agonistas y antagonistas para diagnosis y tratamientos. La invención se abarca ademas agonistas y antagonistas basados en los polipeptidos y en los polinucleótidos de la fosfodiesterasa. La invención se relaciona ademas con agonistas y antagonistas identificados por medio de los metodos de analisis de drogas con los polipeptidos y los polinucleótidos de la fosfodiesterasa como blanco.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/420,190 US6673564B2 (en) | 1999-10-18 | 1999-10-18 | Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2000000081A true DOP2000000081A (es) | 2002-09-16 |
Family
ID=23665445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2000000081A DOP2000000081A (es) | 1999-10-18 | 2000-10-18 | Metodos para usar 22045, una fosfodisterasa humana de nuclosidos ciclicos |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6673564B2 (es) |
| EP (1) | EP1224268A1 (es) |
| JP (1) | JP2003512049A (es) |
| AU (1) | AU8028900A (es) |
| CO (1) | CO5280155A1 (es) |
| DO (1) | DOP2000000081A (es) |
| GT (1) | GT200000181A (es) |
| PE (1) | PE20010808A1 (es) |
| SV (1) | SV2002000204A (es) |
| WO (1) | WO2001029199A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745142B2 (en) * | 1997-09-15 | 2010-06-29 | Molecular Devices Corporation | Molecular modification assays |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| US6930114B2 (en) | 2000-12-13 | 2005-08-16 | Bayer Pharmaceuticals Corporation | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors |
| EP2266552A3 (en) | 2002-03-04 | 2011-03-02 | Merck HDAC Research, LLC | Methods of inducing terminal differentiation |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| AU2002953285A0 (en) * | 2002-12-12 | 2003-01-02 | Protech Research Pty Ltd | Yeast treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798246A (en) * | 1996-03-25 | 1998-08-25 | Incyte Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase |
| US5858694A (en) * | 1997-05-30 | 1999-01-12 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of cancerous lesions |
| US5932465A (en) * | 1997-10-16 | 1999-08-03 | Icos Corporation | Phosphodiesterase 8A |
| DE69900841T2 (de) * | 1998-01-23 | 2002-10-02 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
| US6114111A (en) * | 1998-03-30 | 2000-09-05 | Rigel Pharmaceuticals, Inc. | Mammalian protein interaction cloning system |
| EP0967284A1 (en) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
| US6100037A (en) * | 1999-01-07 | 2000-08-08 | Incyte Pharmaceuticals, Inc. | Human cyclic nucleotide PDEs |
-
1999
- 1999-10-18 US US09/420,190 patent/US6673564B2/en not_active Expired - Fee Related
-
2000
- 2000-10-18 DO DO2000000081A patent/DOP2000000081A/es unknown
- 2000-10-18 CO CO00079327A patent/CO5280155A1/es not_active Application Discontinuation
- 2000-10-18 SV SV2000000204A patent/SV2002000204A/es unknown
- 2000-10-18 PE PE2000001112A patent/PE20010808A1/es not_active Application Discontinuation
- 2000-10-18 GT GT200000181A patent/GT200000181A/es unknown
- 2000-10-18 AU AU80289/00A patent/AU8028900A/en not_active Abandoned
- 2000-10-18 EP EP00970987A patent/EP1224268A1/en not_active Withdrawn
- 2000-10-18 WO PCT/US2000/028806 patent/WO2001029199A1/en active Application Filing
- 2000-10-18 JP JP2001532184A patent/JP2003512049A/ja active Pending
-
2003
- 2003-06-11 US US10/458,839 patent/US20030215898A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20010808A1 (es) | 2001-08-22 |
| WO2001029199A1 (en) | 2001-04-26 |
| JP2003512049A (ja) | 2003-04-02 |
| EP1224268A1 (en) | 2002-07-24 |
| CO5280155A1 (es) | 2003-05-30 |
| AU8028900A (en) | 2001-04-30 |
| US20020081633A1 (en) | 2002-06-27 |
| US20030215898A1 (en) | 2003-11-20 |
| US6673564B2 (en) | 2004-01-06 |
| GT200000181A (es) | 2002-04-11 |
| SV2002000204A (es) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413563A (pt) | compostos e composições como inibidores de atividade do receptor de quìnase de tirosina | |
| NI200700158A (es) | Agonistas glp-1, composiciones, métodos y usos | |
| AR030236A1 (es) | Moléculas similares a il-17 y usos de las mismas | |
| CR9591A (es) | Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina | |
| BR0111125A (pt) | Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos | |
| UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
| EA200501798A1 (ru) | Новые пептиды, которые связываются с рецептором к эритропоэтину | |
| DE602005016446D1 (de) | 5-HT4-Rezeptoragonistenverbindungen | |
| CL2004000526A1 (es) | Compuestos derivados de dibenzofurano, carbazoles, inhibidores de fosfodiesterasa tipo 4; procedimiento de preparacion; y su uso en el tratamiento de trastornos y condiciones inflamatorias, del sistema nervioso central y diabetes insulino resistente. | |
| BRPI0607306A2 (pt) | derivados de quinoxalina como agentes anti-tumor | |
| BRPI0507808A (pt) | métodos de modular a atividade de citocina; reagentes relacionados | |
| AR030554A1 (es) | Moleculas similares a receptores il-17 y usos de las mismas | |
| DE60034450D1 (de) | 22025, eine neue menschliche zyklische nukleotiden phosphodiesterase | |
| CR11562A (es) | Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina | |
| ATE555814T1 (de) | Radioaktive mittel für die in vivo pet-bildgebung von ccr5 | |
| AR028579A1 (es) | Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica | |
| DOP2000000081A (es) | Metodos para usar 22045, una fosfodisterasa humana de nuclosidos ciclicos | |
| AR022940A1 (es) | Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparacion | |
| DK1949903T3 (da) | Selektive A2A-receptor-antagonister til behandling af atrieflimmer | |
| PA8801501A1 (es) | ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA | |
| UY26404A1 (es) | Métodos para usar una fosfodiesterasa humana de nucleotidos cíclicos | |
| ECSP055904A (es) | Polipétidos recombinantes para diagnosticar la infección con el tripanosoma cruzi | |
| Li et al. | Quality of life among patients with rosacea: an investigation of patients in China using two structured questionnaires. | |
| ATE373718T1 (de) | 17867, eine menschliche aminopeptidase | |
| BRPI0512709A (pt) | métodos para prognóstico da resposta terapêutica a agentes atuando no receptor do hormÈnio do crescimento |